Dolby Laboratories (DLB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently ma ...

Q1 2025 Earnings Call Transcript January 29, 2025 Dolby Laboratories, Inc. beats earnings expectations. Reported EPS is $1.14 ...

CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...

Dolby Laboratories Inc (DLB) reports a 13% revenue increase, fueled by robust licensing performance and expanding automotive ...

In a report released yesterday, Steve Frankel from Rosenblatt Securities reiterated a Buy rating on Dolby Laboratories (DLB – Research Report), ...

Dolby Laboratories (DLB) delivered earnings and revenue surprises of 6.54% and 3.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up ...

Dolby Laboratories (NYSE:DLB – Get Free Report) will likely be posting its quarterly earnings results after the market closes ...

Dolby Laboratories (NYSE:DLB) reported its financial results for the first quarter of 2025, surpassing earnings expectations ...

SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Dolby Laboratories Inc. (DLB) on Wednesday reported fiscal first-quarter earnings of $67.8 million. On a per-share basis, the San Francisco-based company said ...

Here's a brief overview of the earnings report. Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up $41.42 million from the same ...